VVOS

Vivos Therapeutics, Inc.

VVOS · CIK 1716166 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$15M
20202024
Net Income−$11M
20202024
Operating CF−$13M
20202024
Free Cash Flow−$13M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B—
Gross Profit$0.0B$0.0B$0.0B$0.0B$0.0B
R&D Expense$0.0B$0.0B$0.0B——
SG&A Expense—————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-2.22$-11.14$-1.04——
EPS (Diluted)$-2.22$-11.14———

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies